Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
about
Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genesLong-term effects of weight-reducing drugs in hypertensive patientsRimonabant for overweight or obesityLong-term pharmacotherapy for obesity and overweightAnti-Obesity Drugs: A Review about Their Effects and SafetyCannabinoids in health and diseaseAM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitorsThe endocannabinoid system as a target for the treatment of cannabis dependenceThe endocannabinoid system as an emerging target of pharmacotherapyNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementAnalogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinityHeavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analysesActivation of the peripheral endocannabinoid system in human obesityRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersCannabinoid pharmacology: the first 66 yearsHypertriglyceridemia: its etiology, effects and treatmentChronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese ratsPrevalence, predisposition and prevention of type II diabetes.The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityThe thrifty lipids: endocannabinoids and the neural control of energy conservationThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsPlasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic miceEvaluating and treating cardiometabolic risk factors: a case discussionPharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndromeNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?The endogenous cannabinoid system and drug addiction: 20 years after the discovery of the CB1 receptorEffect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trialsPharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in MuscleThe CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic isletsEffects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat dietThe cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker ratsCB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptorsExploiting modern cannabinoid pharmacology for therapeutic gain?Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP miceCausality of small and large intestinal microbiota in weight regulation and insulin resistanceThe CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in ratsCannabinoids, eating behaviour, and energy homeostasis.Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.Endocannabinoids, blood pressure and the human heart.Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.
P2860
Q21090979-8C4E7939-F83F-4965-8ED2-F8E20D56BC66Q24239850-0EB46995-815A-40BC-9D31-626347E360DBQ24244078-F28291AD-8096-46D3-885D-062E215B1E20Q24247723-945BA382-CA05-4EE3-80D0-C5E50C96B1A0Q24630947-FDD1C85E-EB35-460E-9506-16E18AF0DD71Q24633884-21B1258F-D640-461B-86A4-D3D28073F86DQ24647198-CC4B4212-82CE-48BD-A551-21C3FF68C4A1Q24648135-3B449A80-CAE4-4F30-9463-CB838C5041DFQ24648473-1D90A4D0-ED34-4317-BF47-FD535EFFB7D3Q24649618-0D5E4ABF-5241-4692-8157-F96A68919221Q24650317-1CA0B18D-EF52-464E-8876-81D08A72FC09Q24654726-08A64C01-8D0D-4C01-8CFD-1719BF9E982AQ24655297-EB42EBAE-20BD-4F80-922F-17973E555F74Q24658031-38CF258B-E318-486F-B23E-64ED01695900Q24670395-BD5AFA22-F87A-4DF9-9123-52EB49DDFC65Q24672914-13EED8AB-9F9A-458E-BD88-F29DD0538353Q24675513-6FD30E00-BED6-4F9D-A498-9566D844E396Q24815863-02CDE358-96A9-422C-ACF9-EC81A4EA53C7Q26765609-DF9E1A5F-295F-47DA-B9C5-9C2413720DFFQ26996134-6EE7B821-F0DF-4340-8946-03F12BF464CAQ27009466-31B10215-F060-4082-B836-8DD1F0CF1F5FQ27344569-8CE1B09F-76E1-4EAA-BE44-B84F46431B33Q28196750-41854A10-09DA-4289-8EF9-012B421D9EABQ28244460-F7A3F4DE-E2DA-4A46-BAFF-E057AEAD05C4Q28277165-9BA0A798-7880-4597-95BD-337937666777Q28280255-0B33E434-668A-4FC0-9ED6-AA734021196DQ28480564-C5DF8DA0-53D0-4C26-8CEB-C8B7760BFE92Q28551556-16F45740-2001-4EE7-8BBB-9211B4810872Q28572048-D57BA2CC-0A1C-415D-ACD4-F1288CE2BF2DQ28576328-10C5D7B1-6D71-4A44-90A8-4EC7D876E21DQ28579415-CEB1E4D3-FFC1-4436-B2F6-778A424C8F13Q28610813-6316F659-0BA1-4814-ABD0-413107FFE9A5Q28728904-E4C01920-101E-431E-92F5-99C6AD940E76Q28732458-6E1BCDE4-69EB-4104-808B-B015F5E9696FQ28828501-33933D5C-D98A-4ECE-AA40-116A1610FFADQ30355922-FAA85E9E-17DF-4625-894A-52E7AC41BBF5Q30357350-CEC1C569-51AE-43BE-9852-FC2CEA2AEE4EQ30366778-D7118179-5103-4FEF-AB40-4D1B03D8D523Q30368944-CCA68440-1B62-4776-A021-8F14FE37CB99Q30391852-65ED24E9-2359-49E2-9907-0C0FF27985CC
P2860
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@ast
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@en
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@nl
type
label
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@ast
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@en
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@nl
prefLabel
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@ast
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@en
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@nl
P2093
P921
P1433
P1476
Effects of the cannabinoid-1 r ...... nce from the RIO-Europe study.
@en
P2093
Aila M Rissanen
André J Scheen
Luc F Van Gaal
Olivier Ziegler
RIO-Europe Study Group
P304
P356
10.1016/S0140-6736(05)66374-X
P407
P577
2005-04-01T00:00:00Z